ClinicalTrials.gg
TerminatedNCT01701063Updated Jul 20, 2016Results posted

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

A Phase 1/2 interventional study of Telaprevir and Peginterferon alfa-2b in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 24 sites in 6 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.

Enrollment
15th of 39
42 · median 30
Started
2013
with 4 others
Phase 1/2
Only one
of the 39
Registered
33rd of 39
by date
Lead sponsor
12 of 39
Vertex Pharmaceuticals Incorporated

Among the 39 studies testing telaprevir in Hepatitis C, this one is the 15th largest by enrollment, is one of 5 that started in 2013, is the only one in phase 1/2, and was the 33rd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing telaprevir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose adjustments if needed before Part B.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ages 3 to 17 years of age
  • Chronic
  • Hepatitis C virus genotype 1a or b at the Screening Visit
  • Subject is judged to be in good health (besides HCV infection) in the opinion of the investigator.
  • Signed form (ICF), and where appropriate, signed Assent Form

Exclusion criteria

Exclusion Criteria:

  • History of or prior evidence of a medical condition associated with chronic liver disease other than
  • Body weight \<15 kg or >90 kg
  • Prior evidence of hepatic decompensation
  • to pegylated interferon/ribavirin (Peg-IFN/RBV)
  • History or other evidence of severe retinopathy or ophthalmological disorder
  • History of non-genotype 1 HCV
  • Participation in drug study as described in Study Protocol
  • Use of prohibited drugs within 7 days or 5 half-lives before the first dose of study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Treatment-Naive or Prior Partial/Null Response

    telaprevir + Peginterferon alfa-2b + Ribavirin

    Drug: Telaprevir · Drug: Peginterferon alfa-2b · Drug: Ribavirin

Interventions

  • 100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration

  • 50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection

    Also known as: PegIntron®

  • 200-mg capsules or 40-mg/mL solution for oral administration

    Also known as: Rebetol®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

    SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (less than \[\<\] lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/High Pure System (HPS) RNA assay version 2.0. The lower limit of quantification was 25 international units per milliliter (IU/mL).

    Time frame: 12 weeks after last planned dose of study drug (up to Week 60)

  2. Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

    SVR24 was defined as an undetectable HCV RNA Levels (\< lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.

    Time frame: 24 weeks after last planned dose of study drug (up to Week 72)

  3. Percentage of Participants With Rapid Virologic Response (RVR)

    The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. RVR was defined as an undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.

    Time frame: Week 4

  4. Percentage of Participants With Extended Rapid Virologic Response (eRVR)

    The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. eRVR was defined as an undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.

    Time frame: Week 4 and Week 12

  5. Percentage of Participants With Undetectable HCV RNA at Week 12

    The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.

    Time frame: Week 12

  6. Percentage of Participants With On-treatment Virologic Failure

    On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Futility rules: 1) HCV RNA \>1000 IU/mL at Week 4; 2) HCV RNA \>1000 IU/mL at Week 12; 3) Detectable HCV RNA after Week 12 to end of treatment.

    Time frame: Baseline up to Week 48

  7. Percentage of Participants With Virologic Relapse

    The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Viral relapse was defined as having detectable HCV at follow-up in participants who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at planned EOT.

    Time frame: 12 weeks after planned EOT (up to Week 60)

  8. Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

    Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by age.

    Time frame: Baseline, On treatment (up to Week 48)

  9. Maximum Plasma Concentration (Cmax) of Telaprevir

    Cmax was measured for telaprevir only.

    Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7

  10. Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir

    Tmax was measured for telaprevir only.

    Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7

  11. Area Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir

    AUC was measured for telaprevir only. AUC 0-t last was defined as the area under the concentration-time curve from the time of dosing to the last measurable concentration. AUC 0-12 hour (AUC 0-12h) was calculated by respecifying predose concentrations as 12 hour concentrations. AUC 0-24h was calculated as AUC 0-12h multiplied by 2. Dose adjusted AUC (AUC 0-24h_Adj) was calculated by multiplying AUC 0-24h by the dose adjustment factor to obtain projected exposures in participants who were misdosed. Data were presented for AUC 0-t last, AUC 0-12h, AUC 0-24h, AUC 0-24h_Adj.

    Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7

  12. Elimination Half-Life (T1/2) of Telaprevir

    T1/2 was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

    Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7

07

Results

Posted Jul 20, 2016
Limitations and caveats
Study was terminated early because it was determined that telaprevir/Peg-IFN/RBV regimen did not present a meaningful therapeutic treatment over existing interferon-free regimens and was unlikely to be used for participants aged 3 to 17 years.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Started131910
Completed13188
Not completed012
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject001
Withdrew: Other001

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.

Time frame:
Baseline up to Week 52
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Participants with SAEs001
Participants with AEs131810
SecondaryPercentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (less than \[\<\] lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/High Pure System (HPS) RNA assay version 2.0. The lower limit of quantification was 25 international units per milliliter (IU/mL).

Time frame:
12 weeks after last planned dose of study drug (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
percentage of participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)69.289.540.0
SecondaryPercentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

SVR24 was defined as an undetectable HCV RNA Levels (\< lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.

Time frame:
24 weeks after last planned dose of study drug (up to Week 72)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Rapid Virologic Response (RVR)

The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. RVR was defined as an undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Rapid Virologic Response (RVR)
percentage of participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Percentage of Participants With Rapid Virologic Response (RVR)69.273.770.0
SecondaryPercentage of Participants With Extended Rapid Virologic Response (eRVR)

The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. eRVR was defined as an undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.

Time frame:
Week 4 and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Extended Rapid Virologic Response (eRVR)
percentage of participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Percentage of Participants With Extended Rapid Virologic Response (eRVR)61.573.760.0
SecondaryPercentage of Participants With Undetectable HCV RNA at Week 12

The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Undetectable HCV RNA at Week 12
percentage of participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Percentage of Participants With Undetectable HCV RNA at Week 1269.289.570.0
SecondaryPercentage of Participants With On-treatment Virologic Failure

On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Futility rules: 1) HCV RNA \>1000 IU/mL at Week 4; 2) HCV RNA \>1000 IU/mL at Week 12; 3) Detectable HCV RNA after Week 12 to end of treatment.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Percentage of Participants With On-treatment Virologic Failure15.45.330.0
SecondaryPercentage of Participants With Virologic Relapse

The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Viral relapse was defined as having detectable HCV at follow-up in participants who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at planned EOT.

Time frame:
12 weeks after planned EOT (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Relapse
percentage of participantsCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Percentage of Participants With Virologic Relapse000
SecondaryNumber of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by age.

Time frame:
Baseline, On treatment (up to Week 48)
Reported as:
Number · participants
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
participantsOverall Participants
Baseline (n = 41)2
On treatment (n = 6)6
SecondaryMaximum Plasma Concentration (Cmax) of Telaprevir

Cmax was measured for telaprevir only.

Time frame:
Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Telaprevir
nanogram per milliliter (ng/mL)Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Maximum Plasma Concentration (Cmax) of Telaprevir4310 ± 11605050 ± 8844060 ± 1500
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Telaprevir

Tmax was measured for telaprevir only.

Time frame:
Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
Reported as:
Median · hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir
hours (h)Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir4.00 (1.92 to 8.00)4.00 (1.98 to 6.02)4.00 (1.50 to 8.00)
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir

AUC was measured for telaprevir only. AUC 0-t last was defined as the area under the concentration-time curve from the time of dosing to the last measurable concentration. AUC 0-12 hour (AUC 0-12h) was calculated by respecifying predose concentrations as 12 hour concentrations. AUC 0-24h was calculated as AUC 0-12h multiplied by 2. Dose adjusted AUC (AUC 0-24h_Adj) was calculated by multiplying AUC 0-24h by the dose adjustment factor to obtain projected exposures in participants who were misdosed. Data were presented for AUC 0-t last, AUC 0-12h, AUC 0-24h, AUC 0-24h_Adj.

Time frame:
Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
Reported as:
Mean · hours*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir
hours*nanogram per milliliter (h*ng/mL)Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
AUC 0-t last39900 ± 1130043300 ± 948035300 ± 12000
AUC 0-12h39900 ± 1130044100 ± 902035300 ± 12000
AUC 0-24h79900 ± 2270088100 ± 1800070600 ± 24100
AUC 0-24h_Adj95700 ± 2980088600 ± 1920076300 ± 22800
SecondaryElimination Half-Life (T1/2) of Telaprevir

T1/2 was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

Time frame:
Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV—0/13 (0%)13/13 (100%)
Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV—0/19 (0%)18/19 (94.7%)
Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV—1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
InfectionInfections and infestations0/130/191/10
Most frequent other events
Showing 10 of 138
Most frequent other events
EventCohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV
HeadacheNervous system disorders8/1316/196/10
PyrexiaGeneral disorders7/1311/198/10
VomitingGastrointestinal disorders8/1312/196/10
NauseaGastrointestinal disorders7/135/195/10
FatigueGeneral disorders7/135/193/10
AlopeciaSkin and subcutaneous tissue disorders7/131/190/10
PainGeneral disorders2/134/195/10
Abdominal painGastrointestinal disorders5/133/191/10
DizzinessNervous system disorders5/135/190/10
Anal pruritusGastrointestinal disorders4/134/193/10

Baseline characteristics

Full analysis set (FAS) included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBVTotal
Mean14.9 ± 2.0610.2 ± 1.574.9 ± 0.8810.4 ± 4.05
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBVCohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBVTotal
Female1113428
Male26614
08

Study locations

24 sites
  • Phoenix, Arizona, United States
  • San Francisco, California, United States
  • Denver, Colorado, United States
  • Washington, District of Columbia, United States
  • Gainesville, Florida, United States
  • Miami, Florida, United States
  • Indianapolis, Indiana, United States
  • Baltimore, Maryland, United States
  • Bronx, New York, United States
  • New York, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Brussel, Belgium
  • Bruxelles, Belgium
  • Wuppertal, Germany
  • Milano, Italy
  • Padova, Italy
  • Pisa, Italy
  • Esplugues de Llobregat, Spain
  • Madrid, Spain
  • Birmingham, United Kingdom
  • Leeds, United Kingdom
  • London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2012
First posted
Oct 4, 2012
Start
Jan 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jul 20, 2016
Last update
Jul 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01701063
Responsible party
Sponsor
First posted
Oct 4, 2012
Start date
Jan 2013
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jul 20, 2016
Last update
Jul 20, 2016

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2b · Ribavirin

Start the discussion